Drugs / Itasetron
Itasetron
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02259985 | Mar → May 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Itasetron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02259985 ↗ |
| Known as | DA-6215 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105109 ↗ |
| Known as | DAU-6215CL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105109 ↗ |
| Known as | Itasetron hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105109 ↗ |
| Known as | U-98079A | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105109 ↗ |
| Modality | Small molecule | — CHEMBL2105109 ↗ |
| Route | Oral | “single oral dose” NCT02259985 ↗ |